Tesaro’s Rolapitant Hits Primary Endpoints, But Still Disappoints
This article was originally published in The Pink Sheet Daily
Executive Summary
The oncology company’s nausea treatment was successful in late-stage trials, but Tesaro may have trouble differentiating the drug once it reaches the market due to a lack of evidence that it can compete with the current standard of care.